Hampson R E, Rogers G, Lynch G, Deadwyler S A
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA.
J Neurosci. 1998 Apr 1;18(7):2748-63. doi: 10.1523/JNEUROSCI.18-07-02748.1998.
In the companion article (Hampson et al., 1998), the ampakine CX516 (Cortex Pharmaceuticals) was shown to produce a marked facilitation of performance of a spatial delayed-nonmatch-to-sample (DNMS) task in rats. Injections of the drug before each daily session produced a marked and progressive improvement in performance at longer delays (>5 sec) that persisted for 7 d after drug treatment was terminated. In most animals (n = 9) the increase in performance carried over to the intervening vehicle for days, whereas in others (n = 3) the effects dissipated within the session according to the pharmacological half-life of CX516. In this article we report firing correlates of simultaneously recorded cells in the CA1 and CA3 fields of the hippocampus over the period in which DNMS performance was facilitated by CX516. Sample and Delay period firing was enhanced by 100-350% under CX516 and increased progressively over days as did DNMS performance. The firing increases were restricted to correct trials only and were largest on trials with long delays. Firing in the intertrial interval was also altered, but in a manner consistent with a previously demonstrated reduction in between-trial proactive interference by CX516. Finally, in animals in which the effects of CX516 were restricted to when the drug was actually present (i.e., no carryover effects), increased cell firing also paralleled the time course of the performance increase. Results are discussed with respect to the actions of ampakines on hippocampal cellular and synaptic processes that underlie DNMS performance.
在配套文章(汉普森等人,1998年)中,安帕金CX516(皮层制药公司)被证明能显著促进大鼠在空间延迟非匹配样本(DNMS)任务中的表现。在每天的实验环节前注射该药物,在较长延迟(>5秒)时能使表现显著且逐步改善,这种改善在药物治疗终止后持续7天。在大多数动物(n = 9)中,表现的提升在接下来的几天内持续存在,而在其他动物(n = 3)中,根据CX516的药理半衰期,其效果在实验环节内就消失了。在本文中,我们报告了在CX516促进DNMS表现的期间,海马体CA1和CA3区域同时记录的细胞的放电相关性。在CX516作用下,样本期和延迟期的放电增强了100 - 350%,并且与DNMS表现一样,在数天内逐渐增加。放电增加仅局限于正确的试验,并且在延迟较长的试验中最大。试验间隔期的放电也发生了改变,但其方式与先前证明的CX516减少试验间前摄干扰一致。最后,在CX516的作用仅限于药物实际存在时(即无持续效应)的动物中,细胞放电增加也与表现提升的时间进程平行。我们将结合安帕金对海马体细胞和突触过程的作用来讨论这些结果,而这些过程是DNMS表现的基础。